2Ozkaya S, Findik S, Atici AG, et al. Cisplatin-based chemotherapy in elderly patients with advanced stage ( III B and IV) non-small cell lung cancer patients [ J ]. Neoplasma, 2011,58 ( 4 ) : 348 - 351.
3Kaira K,Takahashi T, Murakami H,et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer [ J ]. Lung Cancer,2010,67( 1 ) : 120 -123.
4Cho SH, Park LC, Ji JH, et al. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation[J]. Cancer Chemother Pharmacol,2012,70(2) :315 - 320.
5Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyro- sine kinase inhibitors in patients with EGFR-mutated non-small- cell lung cancer:a meta-analysis of 13 randomized trims [ J ]. Clin Lung Cancer,2011,13 (2) : 107 - 114.
6Lim SH, Lee JY, Sun JM, et al. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mu-tation in either exon 19 or 21 [ J ]. ] Thorac Oncol,2014,9 (4) : 506 -511.
7Fukuoka M ,Wu YL,Thongprasert S ,et al. Biomarker analyses and final overall survival results from a phase III, randomized,open-la- bel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung canc- er in Asia (IPASS) [ J]. J Clin Oncol,2011,29 (21) :2866 - 2874.
8Wu YL, Chu DT, Han B, et al. Phase III, randomized, open-label, first-hne study in Asia of gefitinib versus carboplatin/pachtaxel in clinically selected patients with advanced non-small-cell lung cancer:evaluation of patients recruited from China's Mainland [ J ]. Asia Pac J Clin Oncol,2012,8(3) :232 -243.
9Saito H, Murakami S, Kondo T, et al. Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resist- ance after treatment of more than 6 months[ J]. Onkologie ,2012, 35(1 -2) :18 -22.
10Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer [ J ]. Lung Cancer,2009,64( 1 ) :92 -97.
